Telix Pharmaceuticals (TLX) investor relations material

Competitive positioning and business model

• Focus on theranostics, integrating diagnostics and therapeutics for precision medicine.

• Commitment to developing both therapeutic drugs and companion imaging agents for every target.

• Built an in-house commercial team to manage the complex service component of radiopharmaceuticals.

• Established a global supply chain and manufacturing network with over 50 locations, ensuring vertical integration.

• Early investment in manufacturing and licensing to support future product launches.

PSMA diagnostics and prostate cancer franchise

• Holds about 40% market share in PSMA imaging, with steady quarterly growth.

• Market for prostate imaging is expanding 5%-7% annually, driven by increased urologist adoption.

• BiPASS biopsy trial aims to double the addressable market by integrating PET imaging into frontline diagnosis.

• Early and consistent scanning offers competitive advantage through longitudinal patient data.

• New targets and indication expansions are expected to further grow the sector.

Pipeline and disease continuum approach

• Applies a comprehensive approach across prostate, renal, and brain cancers, supporting patients from diagnosis to late-stage care.

• Pipeline includes assets for hormone-sensitive, castrate-resistant, and palliative prostate cancer, as well as renal and glioblastoma indications.

• Imaging is used to support global clinical trials and optimize patient selection and treatment assessment.